CADTH Canadian Drug Expert Committee recommendation: Levodopa/carbidopa intestinal gel (Duodopa -- Abbvie Corporation) indication : Parkinson's disease
The CADTH Canadian Drug Expert Committee recommends that levodopa/carbidopa intestinal gel (LCIG) be reimbursed for the treatment of patients with advanced levodopa-responsive Parkinson disease (PD) who do not have satisfactory control of motor fluctuations and hyper-/dyskinesia despite optimized tr...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, 2018 Aug
|
| Edition: | Version 1.0 |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee recommends that levodopa/carbidopa intestinal gel (LCIG) be reimbursed for the treatment of patients with advanced levodopa-responsive Parkinson disease (PD) who do not have satisfactory control of motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of PD medicinal products, and for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomyjejunostomy tube required for administration |
|---|---|
| Item Description: | "Final" |
| Physical Description: | 1 PDF file (9 pages) |